Ignite Creation Date:
2025-12-26 @ 12:17 PM
Ignite Modification Date:
2026-02-22 @ 7:22 PM
Study NCT ID:
NCT02113800
Status:
COMPLETED
Last Update Posted:
2020-10-28
First Post:
2014-04-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study
Sponsor:
AIO-Studien-gGmbH
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-08
Start Date Type:
None
Primary Completion Date:
2020-04
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-04
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-08
First Submit QC Date:
None
Study First Post Date:
2014-04-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-10-27
Last Update Post Date:
2020-10-28
Last Update Post Date Type:
ACTUAL